Related Experiment Videos
Chemotherapy in ovarian carcinoma
1Department of Oncology ONK, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.
Cancer Surveys
|January 1, 1989
Summary
Chemotherapy for ovarian cancer has evolved, with cisplatin-containing regimens improving outcomes. However, improved non-invasive methods and new agents are crucial for better treatment efficacy and patient survival.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Clinical Pharmacology
Background:
- Ovarian carcinoma treatment has progressed from single agents to cisplatin-based combinations.
- Cisplatin has improved progression-free and overall survival but further advancements are needed.
- Current non-invasive methods for treatment response evaluation are inadequate.
Purpose of the Study:
- To review the evolution of chemotherapy in ovarian cancer.
- To highlight the need for more effective chemotherapeutic agents.
- To emphasize the limitations of current response assessment and the role of second-look laparotomy.
Main Methods:
- Review of historical and current chemotherapy strategies for ovarian cancer.
- Analysis of the efficacy of cisplatin-containing regimens.
- Discussion of diagnostic challenges in treatment response evaluation.
Main Results:
- Cisplatin-based chemotherapy has enhanced treatment outcomes in ovarian cancer.
- Non-invasive response evaluation methods exhibit a high false-negative rate (50-60%).
- Second-look laparotomy remains essential for accurate treatment efficacy assessment.
Conclusions:
- While cisplatin has improved ovarian cancer chemotherapy, novel agents are required.
- Accurate assessment of treatment efficacy necessitates methods beyond current non-invasive techniques.
- Development of a universal prognostic index is valuable for comparative trial analysis.